Rockwood's $6.2 Billion Merger with Albemarle

Thursday, July 17, 2014

The Firm is representing Rockwood Holdings, Inc. in connection with its merger with Albemarle Corporation.  In the merger, each share of Rockwood common stock will be exchanged for $50.65 in cash and 0.4803 of a share of Albemarle common stock, valuing the transaction at approximately $6.2 billion. Upon closing, Albemarle shareholders will own approximately 70% of the combined company and Rockwood shareholders will own approximately 30%. The transaction is subject to shareholder and regulatory approval and other customary closing conditions and is expected to close in the first quarter of 2015.

More >>
 
Stibbe advises Mylan

Thursday, July 17, 2014

Stibbe advises Mylan Inc., the pharmaceuticals company listed on the NASDAQ with a market cap of approximately $19 billion, on the inversion acquisition of Abbott’s non-U.S. developed markets specialty and branded generics business.

More >>
 
White & Case Advises on €580 Million Dual Tranche High Yield Offering by Fives

Thursday, July 17, 2014

Global law firm White & Case LLP has advised joint bookrunners J.P. Morgan, Deutsche Bank, Barclays, BNP Paribas, HSBC and Société Générale on the refinancing of Fives existing senior and mezzanine debt through a high yield bond offering of an aggregate principal amount of €580 million.

The France-headquartered industrial engineering group's offering is split into two tranches – €380 million 4.5 percent senior secured notes due 2021 and €200 million senior secured floating rate notes due 2020. As part of the transaction, Fives also entered into a new €90 million super senior revolving credit facility.
More >>
 
Wragge Lawrence Graham & Co's Life Sciences team advises on ProStrakan's £230 million acquisition of Archimedes

Thursday, July 17, 2014

 

Archimedes is a fast growing European speciality pharmaceutical company that provides advanced treatments within the therapeutic areas of pain, oncology and critical care. Its largest product is PecFent, a fentanyl nasal spray used in the management of cancer pain in patients who are already receiving maintenance opioid therapy for chronic cancer pain.
Archimedes also has a diversified portfolio of promoted and non-promoted pharmaceutical products. It has a strong European footprint with operations in the UK, France, Germany and Spain. It is based in Reading, UK with a development facility in Nottingham. 2013 revenue increased by 33 per cent to £41 million.
More >>
 
Dechert Advises Pemberton on Strategic Relationship with Legal & General and the Launch of a New Direct Lending Platform

Thursday, July 17, 2014

Dechert LLP advised Pemberton Asset Management Holdings Limited (“Pemberton”) on a strategic relationship with Legal & General. The deal sees the creation of a new Direct Lending platform for institutional investors, through which Pemberton will provide much-needed financing to mid-market companies in the UK and Europe. Legal and General has made a 40% equity investment in Pemberton and an initial commitment to invest €250 million in Direct Lending through the Pemberton platform, with further commitments intended in the future. The Pemberton platform is designed to appeal to major insurers and other institutions who wish to offer funding to mid-market companies. It allows those companies to access institutional funding at a time when bank financing is in decline. The transaction was led by Financial Services partner Gus Black.

More >>
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 7 of 2476


Subscribe Now!
Receive our daily newsletter and stay up to date on major lateral moves and other legal market news.
Email:
First:
Last:
Kinney Recruiting prides itself on placing the best lawyers in ideal legal jobs. Our recruiters strive to ensure that all of our placements are the best possible career moves for both candidates and the hiring law firm. If you are thinking about a lateral move, the only choice is Kinney!